Brooktree Capital Management Sells 89 Shares of Eli Lilly and Company (NYSE:LLY)

Brooktree Capital Management decreased its position in Eli Lilly and Company (NYSE:LLY) by 1.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 7,089 shares of the company’s stock after selling 89 shares during the quarter. Eli Lilly and Company comprises 3.3% of Brooktree Capital Management’s investment portfolio, making the stock its 13th largest holding. Brooktree Capital Management’s holdings in Eli Lilly and Company were worth $4,132,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Lipe & Dalton bought a new position in Eli Lilly and Company during the fourth quarter worth about $26,000. Thompson Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company during the third quarter worth about $27,000. Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company during the third quarter worth about $35,000. Optiver Holding B.V. acquired a new stake in shares of Eli Lilly and Company during the third quarter worth about $36,000. Finally, Family CFO Inc acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at approximately $40,000. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of a number of recent research reports. Bank of America lifted their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Wells Fargo & Company lifted their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday. BMO Capital Markets lifted their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Finally, Barclays lifted their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $736.15.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded down $5.59 during midday trading on Wednesday, hitting $775.51. 962,803 shares of the company’s stock were exchanged, compared to its average volume of 3,045,380. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 12 month low of $399.26 and a 12 month high of $800.78. The company’s 50 day moving average price is $761.41 and its 200 day moving average price is $669.21. The firm has a market capitalization of $736.86 billion, a PE ratio of 133.76, a price-to-earnings-growth ratio of 1.61 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the previous year, the company posted $1.62 EPS. The firm’s revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.